BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

384 related articles for article (PubMed ID: 24177261)

  • 1. Endocrine disruption: fact or urban legend?
    Nohynek GJ; Borgert CJ; Dietrich D; Rozman KK
    Toxicol Lett; 2013 Dec; 223(3):295-305. PubMed ID: 24177261
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ECETOC Florence workshop on risk assessment of endocrine substances, including the potency concept.
    Fegert I
    Toxicol Lett; 2013 Dec; 223(3):310-4. PubMed ID: 23558296
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risk assessment of 'endocrine substances': guidance on identifying endocrine disruptors.
    Lewis RW
    Toxicol Lett; 2013 Dec; 223(3):287-90. PubMed ID: 24036001
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Low dose effects and non-monotonic dose responses for endocrine active chemicals: science to practice workshop: workshop summary.
    Beausoleil C; Ormsby JN; Gies A; Hass U; Heindel JJ; Holmer ML; Nielsen PJ; Munn S; Schoenfelder G
    Chemosphere; 2013 Oct; 93(6):847-56. PubMed ID: 23932820
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Endocrine disrupters and human health: could oestrogenic chemicals in body care cosmetics adversely affect breast cancer incidence in women?
    Harvey PW; Darbre P
    J Appl Toxicol; 2004; 24(3):167-76. PubMed ID: 15211609
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Final amended report on the safety assessment of Methylparaben, Ethylparaben, Propylparaben, Isopropylparaben, Butylparaben, Isobutylparaben, and Benzylparaben as used in cosmetic products.
    Int J Toxicol; 2008; 27 Suppl 4():1-82. PubMed ID: 19101832
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Refinement of the ECETOC approach to identify endocrine disrupting properties of chemicals in ecotoxicology.
    Weltje L; Wheeler JR; Weyers A; Galay-Burgos M
    Toxicol Lett; 2013 Dec; 223(3):291-4. PubMed ID: 23467018
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risk assessment of endocrine active chemicals: identifying chemicals of regulatory concern.
    Bars R; Fegert I; Gross M; Lewis D; Weltje L; Weyers A; Wheeler JR; Galay-Burgos M
    Regul Toxicol Pharmacol; 2012 Oct; 64(1):143-54. PubMed ID: 22735369
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Significance of and Challenges in Regulating Endocrine Disruptors - How Regulators and Industry Can Conquer?
    Dhiman SK; Dureja H
    Endocr Metab Immune Disord Drug Targets; 2020; 20(10):1664-1681. PubMed ID: 32504507
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Exposures to Endocrine Disrupting Chemicals in Consumer Products-A Guide for Pediatricians.
    Wong KH; Durrani TS
    Curr Probl Pediatr Adolesc Health Care; 2017 May; 47(5):107-118. PubMed ID: 28526231
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Human exposure to synthetic endocrine disrupting chemicals (S-EDCs) is generally negligible as compared to natural compounds with higher or comparable endocrine activity. How to evaluate the risk of the S-EDCs?
    Autrup H; Barile FA; Berry SC; Blaauboer BJ; Boobis A; Bolt H; Borgert CJ; Dekant W; Dietrich D; Domingo JL; Gori GB; Greim H; Hengstler J; Kacew S; Marquardt H; Pelkonen O; Savolainen K; Heslop-Harrison P; Vermeulen NP
    J Toxicol Environ Health A; 2020 Jul; 83(13-14):485-494. PubMed ID: 32552445
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Human exposure to synthetic endocrine disrupting chemicals (S-EDCs) is generally negligible as compared to natural compounds with higher or comparable endocrine activity. How to evaluate the risk of the S-EDCs?
    Autrup H; Barile FA; Berry SC; Blaauboer BJ; Boobis A; Bolt H; Borgert CJ; Dekant W; Dietrich D; Domingo JL; Gori GB; Greim H; Hengstler J; Kacew S; Marquardt H; Pelkonen O; Savolainen K; Heslop-Harrison P; Vermeulen NP
    Environ Toxicol Pharmacol; 2020 Aug; 78():103396. PubMed ID: 32391796
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fifteen years after "Wingspread"--environmental endocrine disrupters and human and wildlife health: where we are today and where we need to go.
    Hotchkiss AK; Rider CV; Blystone CR; Wilson VS; Hartig PC; Ankley GT; Foster PM; Gray CL; Gray LE
    Toxicol Sci; 2008 Oct; 105(2):235-59. PubMed ID: 18281716
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Human exposure to synthetic endocrine disrupting chemicals (S-EDCs) is generally negligible as compared to natural compounds with higher or comparable endocrine activity. How to evaluate the risk of the S-EDCs?
    Autrup H; Barile FA; Berry SC; Blaauboer BJ; Boobis A; Bolt H; Borgert CJ; Dekant W; Dietrich D; Domingo JL; Gori GB; Greim H; Hengstler J; Kacew S; Marquardt H; Pelkonen O; Savolainen K; Heslop-Harrison P; Vermeulen NP
    Chem Biol Interact; 2020 Aug; 326():109099. PubMed ID: 32370863
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Human exposure to synthetic endocrine disrupting chemicals (S-EDCs) is generally negligible as compared to natural compounds with higher or comparable endocrine activity. How to evaluate the risk of the S-EDCs?
    Autrup H; Barile FA; Berry SC; Blaauboer BJ; Boobis A; Bolt H; Borgert CJ; Dekant W; Dietrich D; Domingo JL; Gori GB; Greim H; Hengstler J; Kacew S; Marquardt H; Pelkonen O; Savolainen K; Heslop-Harrison P; Vermeulen NP
    Toxicol In Vitro; 2020 Sep; 67():104861. PubMed ID: 32360643
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Human exposure to synthetic endocrine disrupting chemicals (S-EDCs) is generally negligible as compared to natural compounds with higher or comparable endocrine activity: how to evaluate the risk of the S-EDCs?
    Autrup H; Barile FA; Berry SC; Blaauboer BJ; Boobis A; Bolt H; Borgert CJ; Dekant W; Dietrich D; Domingo JL; Gori GB; Greim H; Hengstler J; Kacew S; Marquardt H; Pelkonen O; Savolainen K; Heslop-Harrison P; Vermeulen NP
    Arch Toxicol; 2020 Jul; 94(7):2549-2557. PubMed ID: 32514609
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety assessment of personal care products/cosmetics and their ingredients.
    Nohynek GJ; Antignac E; Re T; Toutain H
    Toxicol Appl Pharmacol; 2010 Mar; 243(2):239-59. PubMed ID: 20005888
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Regulation of endocrine-disrupting chemicals: critical overview and deficiencies in toxicology and risk assessment for human health.
    Harvey PW; Everett DJ
    Best Pract Res Clin Endocrinol Metab; 2006 Mar; 20(1):145-65. PubMed ID: 16522525
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of endocrine disrupting chemicals on onset and development of female reproductive disorders and hormone-related cancer.
    Scsukova S; Rollerova E; Bujnakova Mlynarcikova A
    Reprod Biol; 2016 Dec; 16(4):243-254. PubMed ID: 27692877
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Endocrine disrupting chemicals as potential risk factor for estrogen-dependent cancers.
    Rutkowska AZ; Szybiak A; Serkies K; RachoĊ„ D
    Pol Arch Med Wewn; 2016 Aug; 126(7-8):562-70. PubMed ID: 27509913
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.